Cormorant Asset Management, LP's Form 4 filing
MoonLake Immunotherapeutics (MLTX) · filed Oct 10, 2023
- Accession no.
- 0000929638-23-002739
- Filed
- Oct 10, 2023, 4:00 PM ET
- Trade date
- Oct 5, 2023
- Filing delay
- 5 days
- Rule 10b5-1 plan
- Not checked
This filing lists 1 non-derivative transaction and 0 derivative transactions. Open-market purchases total $3.52M. It was filed 5 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Cormorant Asset Management, LPCIK 0001583977 | 10% Owner |
| Chen BihuaCIK 0001599214 | 10% Owner |
| Cormorant Global Healthcare Master Fund, LPCIK 0001618442 | 10% Owner |
| Cormorant Private Healthcare Fund II, LPCIK 0001747677 | 10% Owner |
| Cormorant Private Healthcare Fund III LPCIK 0001817320 | 10% Owner |
| Cormorant Private Healthcare Fund IV LPCIK 0001871297 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Oct 5, 2023 | Class A Ordinary Shares | PPurchaseAcquired | +58,839 | $59.90 | +$3,524,297.23 | 8,494,151 | Indirect |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.